计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A413749-5mg |
5mg |
现货 ![]() |
| |
| A413749-10mg |
10mg |
现货 ![]() |
| |
| A413749-25mg |
25mg |
现货 ![]() |
|
| 英文别名 | 3,3′-[2,4-Hexadiyne-1,6-diylbis[oxy[(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]]]bis[N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-L-prolinamide] | AZD 5582 | AZD-5582 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | AZD5582 |
| 生化机理 | 新型小分子 IAP 抑制剂 AZD5582 能与 cIAP1、cIAP2 和 XIAP 的 BIR3 结构域有效结合,IC50 值分别为 15、21 和 15 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | 含 2 的杆状病毒 IAP 重复序列拮抗剂;含 3 的杆状病毒 IAP 重复序列拮抗剂;X-连锁细胞凋亡抑制因子拮抗剂 |
| 产品介绍 |
AZD5582 是 IAP 拮抗剂,可以有效与 cIAP1,cIAP2 和 XIAP 的 BIR3 结构域结合, IC50 值分别为 15,21,15 nM。AZD5582 诱导凋亡 (apoptosis)。 Information AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains ofcIAP1,cIAP2, andXIAPwithIC50values of 15, 21, and 15 Targets cIAP1 (Cell-free assay); XIAP (Cell-free assay); cIAP2 (Cell-free assay) 15 nM; 15 nM; 21 nM In vitro Human pancreatic cancer cells display different sensitivities to the synthetic IAP antagonist, AZD5582. Treating human pancreatic cancer cells with AZD5582 differentially induces apoptosis, dependent on the expression of p-Akt and p-XIAP. It targets cIAP1 to induce TNF-α-induced apoptosis. AZD5582 induces a decrease of Mcl-1 protein, a member of the Bcl-2 family, but not that of Bcl-2 and Bcl-xL. HNSCC (head and neck squamous cell carcinoma) cell lines SCC25, Cal27, and FaDu show a dose-dependent cytotoxic effect after treatment with AZD5582. In vivo After AZD5582 treatment, tumor growth and weight decrease, whereas cleaved caspase 3 expression increases in Panc-1-derived xenograft model. When administered intravenously to MDA-MB-231 xenograft-bearing mice, AZD5582 results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Following a modest 0.5 mg/kg intravenous bolus dose of AZD5582 in mice, unbound plasma levels remain above the concentrations at which apoptosis induction and cell death are observed in MDA-MB-231 cells over the course of several hours. Although cIAP1 degradation happens very quickly upon exposure to AZD5582 apoptosis induction (as measured by the amount of cleaved caspase-3) takes longer to reach a maximal effect. A single agent AZD5582 does not exhibit broad-based cytotoxicity but instead should be employed in selected tumor settings expected to be sensitive to IAP inhibitors or in rational combinations with other targeted therapies. The dihydrochloride salt of AZD5582 has sufficient aqueous solubility (>7 mg/mL at pH 4−6) to enable formulation for intravenous administration at the projected efficacious doses. With respect to chemical stability, AZD5582 is found to be photostable and hydrolytically stable between pH 4−6, although some amide hydrolysis is observed under strongly acidic (pH < 1) and basic (pH > 8) conditions. In addition, the compound is stable in the plasma of multiple species, with no compound degradation observed after several hours under physiological conditions. Cell Research(from reference) Cell lines:The human pancreatic cancer cell lines including BxPC-3, Miapaca-2, Panc-1, Panc0813, PL45, Capan-1, Capan-2 and AsPC-1 Concentrations:0, 0.01, 0.1, 0.5 μM Incubation Time:72 h Product Describtion: AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis |
| 纯度 | ≥98% |
| IC50 | XIAP, IC50: 15 nM |
|---|---|
| ALogP | 5.317 |
| hba_count | 8 |
| HBD Count | 6 |
| Rotatable Bond | 21 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488201441 |
|---|---|
| 分子类型 | 未知 |
| IIUPAC Name | (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1S,2R)-2-[6-[[(1S,2R)-1-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]hexa-2,4-diynoxy]-2,3-dihydro-1H-inden-1-yl]pyrrolidine-2-carboxamide |
| INCHI | 1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)/t37-,38-,45-,46-,47+,48+,49-,50-,51-,52-/m0/s1 |
| InChi Key | WLMCRYCCYXHPQF-ZVMUOSSASA-N |
| Smiles | CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C(=O)NC3C(CC4=CC=CC=C34)OCC#CC#CCOC5CC6=CC=CC=C6C5NC(=O)C7CCCN7C(=O)C(C8CCCCC8)NC(=O)C(C)NC)NC |
| Isomeric SMILES | C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC |
| MeSH Entry Terms | AZD5582;N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) |
| 分子量 | 1015.29 |
| Reaxy-Rn | 51753401 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=51753401&ln= |
| 溶解性 | Solubility (25°C) In vitro Water: 100 mg/mL (98.49 mM); |
|---|---|
| 敏感性 | 对光线敏感 |
| Water(mg / mL) Max Solubility | 100 |
| Water(mM) Max Solubility | 98.49402634 |
| 分子量 | 1015.300 g/mol |
| XLogP3 | 5.900 |
| 氢键供体数Hydrogen Bond Donor Count | 6 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 19 |
| 精确质量Exact Mass | 1014.59 Da |
| 单同位素质量Monoisotopic Mass | 1014.59 Da |
| 拓扑极表面积Topological Polar Surface Area | 200.000 Ų |
| 重原子数Heavy Atom Count | 74 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1950.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 10 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Hennessy EJ, Adam A, Aquila BM, Castriotta LM, Cook D, Hattersley M, Hird AW, Huntington C, Kamhi VM, Laing NM et al.. (2013) Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).. J Med Chem, 56 (24): (9897-919). [PMID:24320998] |